Presentations & Publications

We are proud of our scientific progress, much of which has been documented via various presentations and publications.

Since 2011, our proprietary platform has enabled the design of three new clinical drug candidates, resulting in four clinical programs. Our scientific progress has been documented in various national and international presentations and publications.

July 2020	Phase I/II, Open-Label, Ongoing Study of Rilzabrutinib (PRN1008), an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Heavily Pretreated Immune Thrombocytopenia Dr. David Kuter et al. ISTH, July 12, 2020
June 2020	BELIEVE-PV Phase II Part B Study: Extended Treatment With PRN1008 (Rilzabrutinib) For Patients With Pemphigus Dr. Dedee Murrell et al. AAD June 12th, 2020
June 2020	Safety and Efficacy of Rilzabrutinib (PRN1008), an Oral Bruton Tyrosine Kinase Inhibitor, in Relapsed/Refractory Patients With Primary or Secondary Immune Thrombocytopenia: Phase I/II Adaptive Study Dr. David Kuter et al. EHA June 12th, 2020
December 2019	Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients With Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia Dr. David Kuter et al. ASH December 7th, 2019.
October 2019	FC04.08 TIP – A Randomized, Double-Blind, Placebo and Active Controlled, Global Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus Dr. Dedee Murrell et al. EADV October 10th, 2019.
September 2019	Preclinical Mechanisms of Action of PRN1008, a Reversible Covalent Bruton’s Tyrosine Kinase Inhibitor in Clinical Development for Pemphigus Langrish C L, Francesco M R, Xing Y, Bradshaw J M, Owens T D, and Nunn P A. Presented at the 49th annual meeting of the European Society for Dermatological Research (ESDR), September 2019.
May 2019	A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors including metastatic urothelial carcinoma (mUC) Piha-Paul S A, Hierro C, Matos I, Boni V, Hahn N, Bitting R, Bauer T, Aggarwal R, Gourlay S G, Meric-Bernstam F, Owens T D, Brameld K, Neale A, Schwartz R, Murray S, Foote P, Ucpinar S, Tabernero J. Presented at The American Association for Cancer Research Bladder Cancer: Transforming the Field, May 2019.
February 2019	Phase 1 Clinical Trial of PRN2246 (SAR442168), a Covalent BTK Inhibitor Demonstrates Safety, CNS Exposure and Therapeutic Levels of BTK Occupancy Smith P F, Redfern A, Shu J, Xing Y, Hartmann S, Francesco M R, Langrish C L, Burns R, Neale A, Owens T D, Gourlay S G. Presented at Americas Committee for Treatment and Research in Multiple Sclerosis – Forum 2019, February 2019

Advancing Promising Therapies

See Our Pipeline